Gain Therapeutics, Inc.
GANX
$1.65
-$0.04-2.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -17.62% | 3.28% | |||
| Gross Profit | 17.62% | -3.28% | |||
| SG&A Expenses | 8.87% | -16.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.67% | -5.96% | |||
| Operating Income | 6.67% | 5.96% | |||
| Income Before Tax | 5.65% | 16.46% | |||
| Income Tax Expenses | -87.24% | 289.02% | |||
| Earnings from Continuing Operations | 14.13% | 9.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 14.13% | 9.03% | |||
| EBIT | 6.67% | 5.96% | |||
| EBITDA | 6.78% | 6.00% | |||
| EPS Basic | 20.53% | 21.15% | |||
| Normalized Basic EPS | 12.77% | 27.57% | |||
| EPS Diluted | 20.53% | 21.15% | |||
| Normalized Diluted EPS | 12.77% | 27.57% | |||
| Average Basic Shares Outstanding | 8.06% | 15.35% | |||
| Average Diluted Shares Outstanding | 8.06% | 15.35% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||